Anti-Biglycan antibody
Specifications
| Product type: | Primary antibody |
| Antigen: | Biglycan |
| Immunogen: | Recombinant protein |
| Species immunized: | Rabbit |
| Isotype: | IgG |
| Applications: | Western Blot (1:500-1:1000); Immunohistochemistry (1:100-1:200); Flow Cytometry (1:40-1:100); Immunoprecipitation |
| Reactivity: | Mouse, Human |
| Clonality (clone number): | Monoclonal, JB71-31 |
| Form: | Liquid |
| Buffer: | Tris-HCl buffer (pH7.4), 1% BSA, 40% glycerol, 0.05% NaN3. |
| Concentration: | 1mg/ml |
| Purity: | Protein A/G affinity purified |
| Storage: | Aliquot and freeze at -20℃. Avoid multiple freeze/thaw cycles. |
| Alternative names: | BGN antibody |
| Biglycan antibody | |
| Biglycan proteoglycan antibody | |
| Bone/cartilage proteoglycan I antibody | |
| Dermatan sulphate proteoglycan I antibody | |
| DSPG1 antibody | |
| PG S1 antibody | |
| PG-S1 antibody | |
| PGI antibody | |
| PGS1_HUMAN antibody | |
| SEMDX antibody | |
| SLRR1A antibody | |
| Small leucine rich protein 1A antibody |
Show More
Target information
Biglycan, a class I small leucine rich proteoglycan (SLRP) present in the extracellular matrix, influences bone cell differentiation and proliferation. Biglycan contains two chondroitin sulfate glucosaminoglycan (GAG) chains attached near its amino terminus, whereas a closely related SLRP, decorin, contains only one. Biglycan deficient specimens possess diminished capacity to produce bone cells precursors, a lessened response to TGFβ, reduced collagen synthesis, and increased apoptosis. Patients with rheumatoid arthritis express increased immunity to biglycan whereas osteoarthritis patients do not, suggesting that higher immunity to SLRPs may play a role in the pathogenesis of inflammatory rheumatic diseases.
Provider
Erpantech Laboratory